Access To Medicine Foundation
  • Who we are
  • What we do
  • Impact
  • Insights & resources
  • News & events
  • Donate
Donate

Who we are

An independent non-profit organisation accelerating progress toward global health equity.

  • About us
  • How we drive change
  • Our strategy 2022 - 2026
  • Governance
  • Team
  • Funders
  • Annual reports

What we do

We catalyse progress toward equitable access to essential medicines in low- and middle-income countries through our work across diverse research areas.

  • R&D-based pharma companies
  • Medical gas companies
  • Generic medicine manufacturers
  • Diagnostics companies
  • Vaccine manufacturers
  • Antimicrobial resistance
  • Diabetes care

Impact

Discover how our work drives real-world progress on access to medicine.

  • Our achievements
  • Voices of our community
  • How we drive change
  • Partner with us

Insights & resources

Discover our evidence-based research, insights and other changemaking tools.

  • Research hub
  • Company profiles & report cards
  • Access insights
  • The Health Equity podcast
  • Health Equity through Her Lens

News & events

Stay informed on our latest events, collaborations, engagements, and Foundation news.

  • News
  • Events & engagements
  • In the media

Follow us

Often searched

Index ranking

Vacancies

10 year analysis

Follow us

  • About us
  • How we drive change
  • Our strategy 2022 - 2026
  • Governance
  • Team
  • Funders
  • Annual reports
  • R&D-based pharma companies
  • Medical gas companies
  • Generic medicine manufacturers
  • Diagnostics companies
  • Vaccine manufacturers
  • Antimicrobial resistance
  • Diabetes care
  • Our achievements
  • Voices of our community
  • How we drive change
  • Partner with us
  • Research hub
  • Company profiles & report cards
  • Access insights
  • The Health Equity podcast
  • Health Equity through Her Lens
  • News
  • Events & engagements
  • In the media

Date

14 November 2026

Access to medicines: innovations not reaching those in need

In an article for The Lancet, Udani Samarasekera examines findings from the 2026 Access to Medicine Index, highlighting progress in pharmaceutical companies’ access planning alongside persistent gaps in affordability, availability and patient reach in low- and middle-income countries.
Read the full article

SHARE

Reports and publications

In an article for The Lancet, Udani Samarasekera examines findings from the 2026 Access to Medicine Index, highlighting progress in pharmaceutical companies’ access planning alongside persistent gaps in affordability, availability and patient reach in low- and middle-income countries. 

The article notes that access plans now cover 69% of late-stage products in development, more than three times the proportion in 2018. However, it highlights that many plans for non-communicable diseases focus primarily on product registration, without addressing whether patients will be able to afford or obtain treatment. It also reports declining company engagement in research and development for priority disease areas, including communicable and neglected tropical diseases. 

The article explores access challenges across several therapeutic areas, including limited access to GLP-1 medicines and insulin, the uneven geographic coverage of cancer medicines, and the exclusion of some middle-income countries from voluntary licensing agreements for long-acting HIV prevention medicines. It also considers how trade policies could affect pharmaceutical supply chains, pricing and companies’ willingness to serve lower-price markets. While some experts welcome the growing integration of access into company strategies, others question whether this is translating into meaningful change for patients and call for stronger action from governments.

Moy Bracken, Head of the Research Unit at the Access to Medicine Foundation, is quoted highlighting the gap between companies’ growing focus on access planning and the impact this has for patients. She also raises the issue of declining industry investment in research and development for priority health needs: "We are at the lowest level since before 2018, [which is concerning because] we need new innovation for mostly infectious diseases that don't have optimum therapies, and secondly because many of these communicable diseases could be global health security threats in the future."

In the media

Read more of our global media coverage
Media

After 20 years, how much has Big Pharma changed on access?

12 November 2026
Media

Weight-loss drug boom risks leaving poorer countries behind, study finds

12 November 2026

Access to Medicine Foundation

Subscribe to our newsletter

Vacancies FAQs Contact us

Follow us

Access to Medicine Foundation is funded by

Terms & conditions Privacy & cookie policy Disclaimer

Copyright 2004 - 2026 Access to Medicine Foundation - All Rights Reserved